KRAS and colorectal carcinoma: Patient cohorts of 4,632 at MD Anderson Cancer Center in Houston, TX; 2,457 in Japan; 4,897 in Brazil; and 2,559 from a Nordic cohort with CRC who underwent genomic profiling, demonstrated KRAS G12C mutational rates of 2.9%, 2.8%, 3.4%, and 3%, respectively (13–15).